Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Autor: Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Andersen-Nissen E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Dintwe OB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Omar FL; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Naicker N; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; and Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa., Jani I; Instituto Nacional de Saude, Maputo, Mozambique., Mgodi NM; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe., Hunidzarira P; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe., Sebe M; Aurum Institute, Tembisa, Gauteng, South Africa., Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Polakowski L; DAIDS, NIAID, NIH, Bethesda, Maryland, United States of America., Ramirez S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Nebergall M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Takuva S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Sikhosana L; Hutchinson Centre Research Institute of South Africa, Johannesburg, South Africa., Heptinstall J; Department of Surgery, Duke University, Durham, North Carolina, United States of America., Seaton KE; Department of Surgery, Duke University, Durham, North Carolina, United States of America., De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Diazgranados CA; Formerly Sanofi-Pasteur, Swiftwater, Pennsylvania, Pennsylvania, United States of America., Koutsoukos M; GSK, Wavre, Belgium., Van Der Meeren O; Previously GSK, Rixensart, Belgium., Barnett SW; Bill & Melinda Gates Foundation, Seattle, Washington, United States of America., Kanesa-Thasan N; Formerly GSK, Rockville, Maryland, United States of America., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Tomaras GD; Department of Surgery, Duke University, Durham, North Carolina, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Mngadi K; Aurum Institute, Tembisa, Gauteng, South Africa., Goepfert P; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Publikováno v: PLoS medicine [PLoS Med] 2024 Mar 19; Vol. 21 (3), pp. e1004360. Date of Electronic Publication: 2024 Mar 19 (Print Publication: 2024).

Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.

Autor: Walsh, Stephen R.^1,2 (AUTHOR) swalsh@bwh.harvard.edu, Gay, Cynthia L.³ (AUTHOR), Karuna, Shelly T.⁴ (AUTHOR), Hyrien, Ollivier⁴ (AUTHOR), Skalland, Timothy⁴ (AUTHOR), Mayer, Kenneth H.^2,5 (AUTHOR), Sobieszczyk, Magdalena E.⁶ (AUTHOR), Baden, Lindsey R.^1,2 (AUTHOR), Goepfert, Paul A.⁷ (AUTHOR), del Rio, Carlos⁸ (AUTHOR), Pantaleo, Guiseppe⁹ (AUTHOR), Andrew, Philip¹⁰ (AUTHOR), Karg, Carissa⁴ (AUTHOR), He, Zonglin⁴ (AUTHOR), Lu, Huiyin⁴ (AUTHOR), Paez, Carmen A.⁴ (AUTHOR), Baumblatt, Jane A. G.¹¹ (AUTHOR), Polakowski, Laura L.¹¹ (AUTHOR), Chege, Wairimu¹¹ (AUTHOR), Anderson, Maija A.⁴ (AUTHOR)

Publikováno v: PLoS Medicine. 6/24/2024, Vol. 21 Issue 6, p1-25. 25p.

Factors explaining pedestrian-involved fatality crashes on National Highways in India.

Autor: Mehdi Naqvi, Hasan¹ (AUTHOR), Tiwari, Geetam² (AUTHOR)

Publikováno v: International Journal of Injury Control & Safety Promotion. Sep2022, Vol. 29 Issue 3, p321-330. 10p.

Vitamin E-Enhanced Liners in Primary Total Hip Arthroplasty: A Systematic Review and Meta-Analysis.

Autor: Cheng, Qian-Yue^1,2 (AUTHOR), Zhang, Bin-Fei¹ (AUTHOR), Wen, Peng-Fei¹ (AUTHOR), Wang, Jun¹ (AUTHOR), Hao, Lin-Jie¹ (AUTHOR), Wang, Tao¹ (AUTHOR), Cheng, Hui-Guang¹ (AUTHOR), Wang, Ya-Kang¹ (AUTHOR), Guo, Jian-Bin¹ (AUTHOR), Zhang, Yu-Min¹ (AUTHOR)

Publikováno v: BioMed Research International. 12/6/2021, p1-10. 10p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.